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Abstract: Thrombocytopenia can arise from various conditions, including myelodysplastic syn-
dromes (MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral
blood smear, identification of accompanying clinical conditions, and characterization of the clinical
course are important for initial assessment of unexplained thrombocytopenia. Increased awareness is
required to identify patients with suspected MDS or BMF, who are in need of further investigations by
a step-wise approach. Bone marrow cytomorphology, histopathology, and cytogenetics are comple-
mented by myeloid next-generation sequencing (NGS) panels. Such panels are helpful to distinguish
reactive cytopenia from clonal conditions. MDS are caused by mutations in the hematopoietic
stem/progenitor cells, characterized by cytopenia and dysplasia, and an inherent risk of leukemic
progression. Aplastic anemia (AA), the most frequent acquired BMF, is immunologically driven and
characterized by an empty bone marrow. Diagnosis remains challenging due to overlaps with other
hematological disorders. Congenital BMF, certainly rare in adulthood, can present atypically with
thrombocytopenia and can be misdiagnosed. Analyses for chromosome fragility, telomere length,
and germline gene sequencing are needed. Interdisciplinary expert teams contribute to diagnosis,
prognostication, and choice of therapy for patients with suspected MDS and BMF. With this review
we aim to increase the awareness and provide practical approaches for diagnosis of these conditions
in suspicious cases presenting with thrombocytopenia.
Keywords: thrombocytopenia; myelodysplastic syndromes (MDS); bone marrow failure (BMF)
syndromes; aplastic anemia (AA); next-generation sequencing (NGS)
1. Introduction
Thrombocytopenia can be associated with a variety of benign and malignant hema-
tological and non-hematological conditions and the investigation of potential causes is
a challenge for clinicians and involved laboratory specialists. Mild and isolated throm-
bocytopenia (platelet count (PLT) 100–150 G/L) is frequently neglected and not further
investigated. In contrast, isolated severe thrombocytopenia (PLT <50 G/L) is often con-
sidered as immune-mediated thrombocytopenia (ITP) and treated with steroids without
further investigations, in accordance with current guidelines [1]. However, more severe
underlying diseases can be potentially missed and the correct diagnosis, consequently,
reached with delay. With the currently available diagnostic modalities, the correct and
timely identification of myelodysplastic syndromes (MDS) and bone marrow failure (BMF)
syndromes can be efficiently done, which is the mainstay for offering patients the most ap-
propriate treatment. With this review we aim to increase the awareness for MDS and BMF,
providing practical approaches in suspicious cases presenting with thrombocytopenia.
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2. Clinical Presentations and Symptoms of MDS and BMF
General practitioners are commonly involved in the initial diagnostic assessment of
patients with unclear thrombocytopenia. Thus, their role is crucial in identifying suspi-
cious cases of both MDS and BMF and initiate the correct diagnostic assessments timely.
Knowledge on the characteristic clinical features for MDS or BMF are therefore helpful.
2.1. Myelodysplastic Syndromes
With ageing of the general population, and the introduction of next-generation se-
quencing (NGS) into clinical practice, patients with clonal hematological conditions are
increasingly identified. Therefore, in elderly patients with unexplained cytopenia, includ-
ing isolated thrombocytopenia, clonal disorders, such as MDS and other related myeloid
neoplasms, should always be considered as potential differential diagnosis.
2.1.1. Definition and Pathogenesis of MDS
Patients with unexplained chronic thrombocytopenia should direct awareness to-
wards a potentially underlying myeloid neoplasm, especially in elderly patients with
worsening bi- or pancytopenia, or in individuals with previous exposure to chemo- or
radiotherapy [2]. MDS are heterogeneous hematopoietic stem and progenitor cell (HSPC)
disorders characterized by cytopenia, dysplasia, inflammation, and a propensity to evolve
towards secondary acute myeloid leukemia (AML) [3,4]. MDS originate from HSPCs
affected by somatic mutations in leukemia-associated genes (SM-LAGs). These mutated
HSPC are selected through a stochastic drift that is influenced by a variety of cell-intrinsic
and cell-extrinsic mechanisms over a variable duration of time [5].
2.1.2. Epidemiology of MDS and Risk Factors
As in many other cancers, MDS and related myeloid disorders are diseases of elderly
patients with a median age at presentation above 70 years and male predominance. The
exposure to mutagenic agents, such as chemotherapy, radiotherapy, pesticides, insecticides,
benzoyl, and solvents, are recognized risk factors [6–9]. The age-adjusted incidence rate of
MDS is between 3–4 per 100,000 patient-years in western countries, with an increase of the
age-specific incidence rate to more than ten-fold for individuals >70 years of age [2,10,11].
Incident cases of MDS are assumed to rise substantially in the forthcoming years, due to
population ageing, increased cancer survivorship, and improvements in diagnostic accu-
racy for the detection of clonal hematopoiesis. MDS can also occur in children and younger
to middle-aged adults (aged <50 years), in whom an underlying germline predisposition
has to be actively explored [12].
2.1.3. Presentation and Symptoms of Patients with MDS
Depending on the cell lineages affected by cytopenia, MDS patients suffer from a vari-
ety of symptoms at presentation, which comprise fatigue, dyspnea, tachycardia, bacterial in-
fections, or mucocutaneous bleeding [3]. A substantial number of patients with chronic and
mild cytopenia can be asymptomatic. In MDS patients, anemia (usually macrocytic) is the
predominant abnormality in the peripheral blood (80–85%), followed by thrombocytopenia
(30–65%) and neutropenia (40–50%) [13]. Sometimes, patients present with overlapping
features of myelodysplasia with cytopenia as well as myeloproliferation. In such cases, pa-
tients can present with splenomegaly and accompanying monocytosis (≥1.0 G/L and ≥10%
of all leukocytes) in chronic myelomonocytic leukemia (CMML), granulocytosis, or even
thrombocytosis in other rare MDS/MPN (myelodysplastic syndrome/myeloproliferative
neoplasm) overlap conditions [14]. The association of clonal hematopoiesis with a broad
range of autoinflammatory and autoimmune manifestations is generally underestimated.
These manifestations may be of paraneoplastic origin and should direct further investiga-
tions for an underlying myeloid or lymphatic malignancy [15,16].
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2.2. Bone Marrow Failure Syndromes
BMF can be separated in acquired and inherited BMF (iBMF) forms. While acquired
forms can affect children and adults, congenital forms are particularly more frequent in
children less than five years of age, but also in adolescents and young adults. Unusual
presentation of congenital forms may show a late presentation even after the fourth decade
of life, may be oligosymptomatic, and can be therefore particularly difficult to diagnose.
2.2.1. Definition and Pathogenesis of BMF
Aplastic anemia (AA) is a rare BMF. This non-malignant disease is characterized by
pancytopenia and bone marrow hypoplasia of varying severity. Aplastic anemia will be
considered idiopathic when no underlying cause can be identified. Idiopathic AA results
from autoimmune mediated destruction of early precursors of hematopoietic cells [17,18].
AA can be related to paroxysmal nocturnal hemoglobinuria (PNH), which is a clonal
hematopoietic stem cell disorder with various features including hemolytic anemia, bone
marrow failure, and thrombosis. Other pathophysiologic mechanisms may also be in-
volved in secondary forms of AA. Direct damage of hematopoietic cells may occur in
patients exposed to irradiation, drugs or chemicals, and may represent an underlying cause
of AA. Different viral infections including cytomegalovirus (CMV), Epstein–Barr virus
(EBV), dengue virus, parvovirus b19, human herpes virus 6 (HHV6), human immunodefi-
ciency virus (HIV), and disseminated adenovirus infections [19] can be associated with the
development of AA. Seronegative hepatitis has been reported in 5–10% of patients with
AA [20–22]. Accelerated attrition of telomeres [23–25] and acquired somatic mutations of
genes related to myeloid diseases [26–28] are associated with an increased risk of MDS,
AML, and early death.
iBMF represent a relevant cause of AA in children and are frequently related to
germline mutations (Supplemental Table S1). Evidence of such syndromes may be obvious
in patients with BMF. On the other hand, the clinical changes can be subtle and the
syndrome can only be diagnosed when the hematological picture becomes manifest with
severe cytopenias. In this regard, various syndromes exist. Fanconi anemia (FA) [29]
is caused by a defect in the DNA repair mechanisms, predisposing to various tumors.
Telomeropathies involve a wide variation of genetic disorders caused by mutations in
genes of the telomerase or the DNA damage response complexes. The most characteristic
syndrome is dyskeratosis congenita (DC) [25]. Shwachman–Diamond syndrome (SDS) [30]
is caused by variants of pathogenic genes that affect the biogenesis and mitosis of ribosomes.
Congenital amegakaryocytic thrombocytopenia (CAMT) [31] results mainly from mutations
in the oncogene of the virus myeloproliferative leukemia (MPL) responsible for encoding
the thrombopoietin receptor.
2.2.2. Epidemiology of BMF and Risk Factors
AA has a variable geographic distribution, the global incidence ranging from 0.7 to
7.4 cases per million inhabitants per year, with 2- to 3-fold higher rates in Asia than in
Europe and the U.S. The disease can present at any age, but the presentation is bimodal with
a peak in young adults and the elderly. AA affects both sexes in similar proportions [32,33].
Ethnicity and some specific human leukocyte antigen (HLA) characteristics have been
associated with higher predisposition to develop AA, higher frequency of small PNH clones
and response to immunosuppression [34–38]. Environmental factors may be relevant, such
as frequent exposure to benzene-based products [39]. Clonal hematopoiesis is prevalent in
AA, and some mutations impact on clinical outcomes. At present, however, prediction of
clinical significance is often difficult [40]. The iBMF appear mainly between 2 and 5 years
of life, but can manifest at any age during childhood or adolescence. More rarely, diagnosis
will be reached later in life [41].
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2.2.3. General Presentation and Symptoms of Patients with BMF
Patients with AA usually refer symptoms of onset in the previous weeks that are
related to the type and number of cytopenias. Symptoms are frequently related to ane-
mia, mainly fatigue, and dyspnea on exertion. Bleeding symptoms are also common
including easy bruising, menorrhagia, skin or enoral petechiae typically occurring when
thrombocytopenia is significant. Although less frequent, infections can be life-threatening,
mainly affecting patients with profound neutropenia [18,42]. Other than that, the clini-
cal examination is classically negative, with absence of lymphadenopathy, splenomegaly
or hepatomegaly.
In AA patients, a positive family history including other members affected with
cytopenia or malignancy suggests an iBMF. The presence of abnormal clinical features, such
as short stature, thumb, or radial ray and/or skeletal abnormalities, microcephaly, hypo- or
hyperpigmentation (café au lait spots), eye, renal, or gonadal malformations are changes
related to FA [29]. The presence of abnormal pigmentation of the skin, nail dystrophy
affecting hands and feet, and oral leukoplakia is considered to be the classic presentation of
DC. In addition, premature gray hair and pulmonary fibrosis have been reported [43]. SDS
can have a broad clinical phenotype with skeletal abnormalities, steatorrhea consequently
to exocrine pancreatic dysfunction, and recurrent infections [30]. CAMT presents with
isolated thrombocytopenia and reduced megakaryocytes in the bone marrow without birth
defects characteristic of other iBMF [31].
3. Diagnostic Approach for MDS and BMF
In the following, we will describe our suggest stepwise diagnostic approach, as
summarized in Figure 1.
3.1. Primary Diagnostic Work-Up
The exclusion of other conditions associated with thrombocytopenia is the mainstay
for the primary work up (Table 1). Complete blood counts (CBC) including white blood
count (WBC) with a full differential, red blood cell (RBC) analysis of hemoglobin, hemat-
ocrit, and RBC indices (including mean cellular volume, MCV) and reticulocyte counts are
essential. In patients with MDS or BMF, peripheral blood parameters reveal evidence of
different combinations of cytopenia. Anemia is frequently macrocytic (increased MCV),
and reticulocytes are usually significantly reduced [44]. The immature platelet fraction (IPF)
can be helpful to identify younger platelets and is increased in peripheral consumption.
Microscopic cytomorphologic examination of the peripheral blood smear has to be done in
cases with unexplained cytopenia to identify morphological RBC abnormalities (schisto-
cytes, anisocytosis, and poikilocytosis), dysplasia, or the presence of cell line precursors
and blasts.
Substrate deficiency should be excluded by determination of serum folate, transcobal-
amin, iron, total iron binding capacity (TIBC), and ferritin. Parameters that may be indica-
tive for hemolysis, such an increased rate of reticulocytes, lactate dehydrogenase (LDH),
and bilirubin combined with decreased haptoglobin, with or without a positive direct
antiglobulin test (DAT/direct Coombs test), should cast suspicion on hemolytic anemia
(PNH, autoimmune hemolytic anemia). Viral infections such as HIV, Parvovirus B19, CMV,
EBV, hepatitis B (HBV), and C virus (HCV) should be excluded. Lymphoid neoplasms
or plasma cell neoplasms can be identified with protein electrophoresis, immunofixation
and free light chain assays. Thyroid-stimulating hormone (TSH), antinuclear antibodies
(ANA), antineutrophil cytoplasmic antibodies (ANCA) and rheumatoid factor (RF) direct
towards a potential rheumatological disorder and abdominal ultrasound might identify
an underlying liver disease, splenomegaly, or lymphoma. Thalassemia and other forms
of hereditary hemoglobinopathies should be excluded according to ethnicity as well as
personal and family history.
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Figure 1. Stepwise diagnostic approach to thrombocytopenia in patients with suspected myelodysplastic syndromes (MDS)
or bone marrow failure (BMF) syndromes.
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Table 1. Primary laboratory evaluation in patients with unexplained thrombocytopenia.
Laboratory Test Provide Information on
Automated blood count (MPV, IPF), reticulocytes CBC. Quantitative values. Platelet size and production capacity of thebone marrow.
Blood smear Pseudothrombocytopenia, schistocytes, dysplasia, blasts, general cell line;changes and maturation
Substrates (folate, Vitamin B12/holoTC, iron tests) Substrate deficiency
PT, INR, aPTT, Fibrinogen Coagulopathy (DIC, TTP)
Liver and kidney tests function Liver or kidney disease
Infections (HIV, HCV, HBV, CMV, EBV, Parvo B19) Viral infection
Protein electrophoresis with immunofixation Lymphoid neoplasms, plasma cell neoplasms
Free light chains plasma cell neoplasms
LDH, bilirubin, haptoglobin, DAT Hemolysis
TSH (ANA, ANCA, RF) Autoimmunity
Abdominal ultrasound Liver disease, splenomegaly, lymph nodes enlargement
CBC: complete blood count; DAT: direct antiglobulin test; DIC: disseminated intravascular coagulation, holoTC: holotranscobalamin; IPF:
immature platelet fraction; LDH: Lactate dehydrogenase; MPV: mean platelet volume; TTP: thrombotic thrombocytopenic purpura.
3.2. Secondary Diagnostic Work-Up
Patients with suspicious findings with worsening/relevant cytopenia and exclusion
of other causes in the primary work-up should be referred to specialized centers for more
detailed investigations. Morphological evaluation of peripheral blood (PB), bone marrow
(BM) histology, and cytology with iron staining/assessment as well as cytogenetic analysis
are mandatory for the assessment of MDS and BMF. Cytogenetics is indispensable to
determine clonality and assess the disease-based risk in case of MDS [45,46]. Currently,
asservation of bone-marrow samples for eventual molecular diagnostics with NGS is also
advisable. NGS with myeloid panels is instrumental in all patients with unclear cytopenia
as well as MDS with normal cytogenetics since it might prove clonality, refine prognosis,
contribute to predicting treatment response, and serve as measurable residual disease
(MRD) marker after allogeneic hematopoietic stem cell transplantation (allo HSCT) [47].
3.3. Peripheral Blood Smear
Bi- or pancytopenia is common in both MDS and BMF; however, at their onset, single
cell lineages can also be affected. Non-regenerative anemia is almost a constant finding,
with suppression of reticulocyte production. RBC macrocytosis is a common feature for
MDS and BMF; however, relevant anisocytosis and/or poikilocytosis is predominantly
found in MDS [42]. The observation of iron deficiency in the presence of pancytopenia
should direct the investigations towards PNH. A normal WBC does not exclude an ab-
normal differentiation with neutropenia. Neutropenia can occur in varying degrees of
severity. Lymphocyte count is generally decreased in MDS but normal in BMF [48]. In
some cases, an expansion of large granular lymphocyte (LGL) can accompany AA. Its
clinical relevance remains frequently unclear and it can be difficult to distinguish from LGL
leukemia [41,49,50]. Monocytopenia may expand the differential diagnosis to hairy cell
leukemia. Cytomorphologic examination of the peripheral blood smear has to be done
microscopically to assess for morphologic abnormalities of RBC, dysgranulopoiesis and
abnormal platelets. The presence of hematopoietic precursors with or without blasts is sug-
gestive for an underling chronic myeloid neoplasm, whereas blasts without hematopoietic
precursors (hiatus leucaemicus) is characteristic of acute leukemia. Atypical lymphocytes,
e.g., hairy cells, suggest a lymphoproliferative disorder [42,51].
3.4. Bone Marrow Cytomorphology
Bone marrow cyto- (aspirate) and histomorphology (biopsy) are essential and com-
plementary for the diagnosis of MDS and BMF. The examination of bone marrow smears
reveals quantitative information about cellularity, assessment of the different hematopoietic
lineages (granulopoiesis, erythropoiesis, megakaryopoiesis), and the maturation stages.
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Increase of blasts or infiltrations of pathologic cell populations may be identified. Scant
amount of bone marrow particles can be found in BMF and sometimes in MDS; however, a
dry tap is unusual in BMF and suggests other diagnoses [52]. Quantitative and qualitative
dysplastic morphological alterations of bone marrow precursors and peripheral blood cells
are still fundamental for classification of MDS [44]. According to the 2016 World Health
Organization (WHO) update, the presence of at least 10% of dysplastic cells in at least
one hematopoietic lineage in the bone marrow is sufficient for a diagnosis of MDS [53].
Nevertheless, dysplastic features of hematopoiesis occur also in healthy individuals. On
the other hand, substantial clonal hematopoiesis may exist in cases with less than 10%
dysplasia. Following iron staining of the bone marrow smears, evidence of more than 15%
ring sideroblasts (that result from mitochondrial iron accumulation) [44] or, in the presence
of characteristic SF3B1 mutations, more than 5%, is a diagnostic criterion for MDS with
ring sideroblasts). Increase of marrow myeloblasts to 5% to 19% assign cases to advanced
MDS with excess of blasts 1 and 2 (EB-1 or EB-2).
3.5. Bone Marrow Histopathology
Bone marrow trephine biopsies reveal information on cellularity, lineage distribution
within the marrow space, and stroma fibrosis. In addition, bone marrow biopsy improves
the characterization of megakaryocytes, blast quantification, and characterization of clusters
of blasts: this phenomenon is known as “atypical localization of immature precursors”
(ALIP). Identification of MDS with fibrosis and also hypoplastic MDS (hMDS) is rendered
possible [44]. Likewise, histopathology is essential for the discrimination of MDS cases
from overlapping disorders. For better discrimination of MDS from CMML, monocytic
cells can be identified by immunohistochemistry, e.g., staining for CD68. Histopathology
is crucial for the diagnosis of BMF and requires representative and sometimes repetitive
sampling [54]. Aplastic and hypocellular BM is defined by a cellularity below 10% or 30%,
respectively. The quality of the trephine biopsy is particularly important in the elderly,
who have physiologically hypocellular marrow [55]. A typical AA marrow presents
with variable amounts of residual hematopoietic cells with large fat spaces. Abundant
plasma cells, lymphocyte and mast cell hyperplasia accompany the picture. Stromal cell
hyperplasia can simulate normal cellularity and the increase in lymphocytes and/or mast
cells sometimes pretend an infiltrative character. In such cases, immunohistochemistry or
flow cytometry may be required to rule out a lymphoid neoplasms or mastocytosis [56].
Erythropoiesis nests forming “hot spots” are characteristic as well [51]. A certain degree
of dyserythropoiesis with megaloblastic changes is frequently found in AA and needs to
be carefully distinguished from MDS. Granulopoiesis and megakaryocytes are usually
severely diminished or absent, without relevant dysplastic changes. Immunohistological
staining allows the identification, quantification as well as topographic distribution of blasts,
megakaryocytes, abnormal cells and infiltrates. Not infrequently, AA can be associated
with lymphoproliferative disorders [56–58].
3.6. Multiparameter Flow Cytometry
For MDS, flow cytometric scores have been developed to contribute to the diagnostic
process [59]. Dysplastic changes can be identified, e.g., by sophisticated interpretation
of surface marker abnormalities in the myeloid compartment, and immature progenitor
compartments can be identified. However, NGS seems to replace flow cytometry increas-
ingly for the detection of clonality in MDS [60]. Nonetheless, flow cytometry remains
essential to exclude other diagnoses, such as hairy cell leukemia. In patients with AA or
hypoplastic MDS, subclones of PNH may be identified, which contribute in confirming the
diagnosis. PNH clones are characterized by absence or severe deficiency of glycosylphos-
phatidylinositol (GPI)-anchored proteins, CD55, and CD59. Loss of the respective antigens
is detected by staining with monoclonal antibodies and a reagent known as fluorescent
aerolysin (FLAER) [61].
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3.7. Cytogenetics
In around 50% of patients with de novo MDS and in around 80% of patients with
therapy-associated MDS (t-MDS), clonal cytogenetic aberrations can be identified by chro-
mosome banding analyses. Entities, such as MDS with isolated 5q deletion according to
the WHO classification, can only be defined by karyotyping. Other examples of typical
clonal cytogenetic alterations in MDS are abnormalities of chromosomes 7 or 17p. It should
be considered that loss of the Y chromosome can be either clonal or age-related in male
patients, depending on the proportion of aberrant metaphases [53]. Additionally, the kary-
otype has a central role for the revised International Prognostic Scoring System (IPSS-R)
that discriminates five cytogenetic risk groups [46,62]. In AA, cytogenetic abnormalities
can be present in up to 15% of patients [63]. Frequent anomalies include trisomy 8, uni-
parental disomy of 6p, 5q-, anomalies of chromosome 7 and 13. While abnormalities of
chromosome 5 and 7 are very consistent with an underlying MDS, the finding of other
abnormalities is not diagnostic. AA patients with del(13q) were reported with favorable
response to immunosuppression [64,65]. Fluorescence in situ hybridization (FISH) allows
detecting chromosome abnormalities of interphase nuclei also in the case of insufficient
chromosome banding analysis. Vital cells are not required for interphase FISH. For patients
with suspected or proven MDS, comprehensive interphase probe panels detecting frequent
cytogenetic alterations, e.g., of chromosomes 7/7q, 5q, or 17p, may be used. Besides the
detection of relevant cytogenetic alterations, FISH allows to confirm or further clarify
doubtful results of chromosome banding analysis. At follow-up, the percentage of aberrant
interphase nuclei in the case of a previously detected abnormality can be monitored at a
sensitive level. Single nucleotide polymorphism (SNP) array analysis allows capturing
both DNA copy number and SNP based genotype at a submegabase resolution. This facili-
tates the detection of small areas of loss of heterozygosity (LOH) of uniparental disomy
(UPD) [66] and submicroscopic changes on a cryptic level [60,67]. However, array analyses
are increasingly loosing relevance since the introduction of NGS for diagnosis of MDS.
3.8. Next-Generation Sequencing
The detection of SM-LAGs by NGS has gained increasing importance in hematological
molecular diagnostics laboratories. NGS allows high-throughput screening for variants
that are relevant for diagnosis, classification, risk stratification and, treatment monitoring in
patients with hematologic malignancies [68]. At present, targeted sequencing using specific
panels covering hotspots of a selection of relevant genes is the method of choice for hemato-
logic diagnostics [69,70]. Examples for commercially available myeloid NGS panels include
the Illumina TruSight Myeloid panel (Illumina Switzerland GmBH, Zürich, Switzerland),
the Oncomine Myeloid panel (Thermo Fisher Scientific, Reinach, Switzerland), and the
Human Myeloid Neoplasms QiaSeq DNA Panel (Qiagen, Rotkreuz, Switzerland). These
panels cover hotspots in 25 to more than 50 genes. NGS-targeted sequencing shows a
sensitivity between 1% and 5–10%, depending on allele coverage and type of NGS. Each
NGS platform has its own technical limitation calling for caution to avoid false positive
and negative results. Interpretation of genetic variants relies on thorough assessment
using appropriate databases, and the differentiation of a MDS associated mutation from a
germline variant needs to be addressed whenever a variant is close to 50% variant allele
frequency (VAF). The knowledge on MDS-related markers and the information collected
in variant databases are undergoing constant changes, so that variant interpretation can
change over time.
3.9. Role of Next-Generation Sequencing in BMF
BMF have a high complexity on the molecular level. The molecular profile may show
overlaps with myeloid disorders, rendering the discrimination from MDS difficult. In
children and young adults with BMF, it will be necessary to rule out congenital forms
by molecular methods, while in older adults, the focus will be more likely on somatic
mutations. NGS allows investigating both relevant germline and somatic mutations. The
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choice of the most appropriate NGS gene panel is of utmost importance. Users of NGS
technology should be aware that new pathogenic relevant genes or non-coding regions, like
promoter or intronic regions, can be discovered after the design of the gene panel. For this
reason, whole exome sequencing is a method of choice for germline panels, allowing a re-
analysis of further genes without repetition of the analysis (caveat: non-coding regions are
usually missing). Copy number variation (CNV) is a phenomenon frequently observed in
BMF where large sections of DNA can be deleted or duplicated; sometimes whole genes are
missing. CNV can be detected by array-based comparative genomic hybridization (Array-
CGH) technology, which covers large parts of the genome, or multiplex ligation-dependent
probe amplification (MLPA) analysis, which focuses on specific genes or genomic regions.
Cytogenetic analysis is applied for detection of large chromosomal rearrangements, either
by karyotyping (for large rearrangements) or by FISH (for specific rearrangements).
The molecular diagnosis of some iBMF can be straightforward, while others are very
complex and heterogeneous [43,71–74]. DC is heterogeneous and shows complex clinical
criteria in concordance with complex genetic findings [75]. For suspected iBMF without
a specific clinical pattern, more and more heterogeneous clinical and molecular findings
are identified, resulting in newly recognized disease entities [76]. In addition to germline
variants, patients with different BMF entities may carry somatic mutations.
3.10. Discrimination of Germline from Somatic Mutations
Somatic NGS analysis in MDS yields a variety of different genetic variants in numerous
genes. Most of these variants can be assigned to two groups: first, clonal alterations in
relation to the hematologic disorder, and, second, benign germline variants. The first group
comprises driver mutations, contributing to the malignant development, and additional
passenger mutations. By now, numerous driver mutations are known, including RNA
splicing, DNA methylation, transcription, chromatin modification, signal transduction,
DNA repair, cohesin complex and associated proteins, RAS pathway, a variety of other
signaling molecules, and pathways such as TP53 [77]. The second group, the benign
variants, show always either 50 or 100% VAF, as they are germline variants, unless a somatic
deletion at this specific locus has happened, and they are usually listed in databases (UCSC,
gnomAD, others). However, there can be variants with a VAF close to 50%, or sometimes
distinctly above 50%, which are neither clearly benign nor clonal. Loss of heterozygosity
(LOH) needs to be considered in such cases (variant clearly over 50% VAF). Alterations in
the DX41, RUNX1, GATA2, and TP53 genes are potentially present in the germline and can
cause a predisposition to AML or MDS. For solid tumors, the American College of Medical
Genetics (ACMG) developed recommendations for the reporting of presumed germline
pathogenic variants (PGPVs) [78]. Confirmatory germline testing should be performed in a
specialized laboratory, and positive results have to be explained to the patient by clinicians
with genetic expertise.
4. Characterization of MDS and BMF
4.1. Challenges in Finding the Diagnosis of MDS and BMF
The approach to suspected MDS of BMF is work-intensive and requires expertise
in the interpretation and integration of the laboratory results from various diagnostic
modalities, which is best achieved within an interdisciplinary pathological review board.
The conditio sine qua non for MDS is the presence of unexplained cytopenia accom-
panied by signs of dysplasia in the peripheral blood or bone marrow and, at later stages,
increase of immature myeloid blasts. In many instances, cytomorphology alone is not
sufficient to confirm or exclude MDS. In such cases, bone marrow cytogenetic analyses can
help to identify clonality with chromosome abnormalities in ~50% of all affected patients.
NGS has increased the diagnostic sensitivity for the identification of clonal markers of
hematopoietic cells in most MDS patients. However, SM-LAGs may also be present in AA,
showing some overlap between AA and hMDS, and the distinction may be challenging
(Table 2).
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Table 2. Common findings and differences between hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) [52].
Parameters Hypoplastic MDS Aplastic Anemia
Cytopenia Present Present
BM cellularity Hypocellular Aplastic (<10% cellularity or significantly hypocellular)
BM hematopoiesis
Erythropoiesis Present Present in nests, “hot spots”
Granulopoiesis Present Typically decreased
Megakaryopoiesis Present Decreased or absent
BM fat replacement Possible Typical
Dysplasia
Erythroid dysplasia Frequent Possible
Granulocytic dysplasia Frequent Normal morphology
Megakaryocytic dysplasia Frequent Normal morphology
Ring sideroblasts Possible Absent
Blasts Variable Absent
CD34+ or CD117+ immunohistochemistry Normal or increased No increase
Marrow fibrosis Possible Absent
PNH clone Unusual Frequent
Splenomegaly at diagnosis Possible Absent
Karyotype Abnormal ~50% Clonal abnormality possible (~12%)
Recurrent cytogenetic abnormalities -Y, del(11q), −5/del(5q), del(12p), del(20q), −7/del(7q), +8, +19, i(17q),inv(3)/t(3q)/del(3q)
At Diagnosis: del(13q), +8
Evolution: −7, −5/del (5q), del(20q)
Complex cytogenetics
(≥3 abnormalities) Possible Absent
Acquired CN-LOH Possible Possible (<20%)
Somatic mutated genes SF3B1, SRSF2, U2AF1, ZRSR2, TET2, DNMT3A, IDH1, IDH2, ASXL1, EZH2,RUNX1, NRAS, BCOR, TP53, STAG2
Particularly PIGA, ASXL1, BCOR, BCORL1;
5–52% of patients will present MDS-associated mutations
Germline mutations Should be investigated in patients with suspicion of underlyinggermline predisposition.
Should be investigated in patients with suspicion of underlying
congenital BMF.
BM: bone marrow; PNH: paroxysmal nocturnal hemoglobinuria CN-LOH: copy number-neutral loos of heterozygosity.
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AA has phenotypic overlaps with many other hematological disorders, including
hypoplastic forms of MDS, AML, and lymphoblastic leukemia (ALL). Moreover, LGL,
PNH, and iBMF can manifest with a hypocellular BM. The diagnostic discrimination
of these entities is demanding, as AA can occur at any age, lacks specific diagnostic
markers, and remains a diagnosis of exclusion. For iBMF, such as telomeropathies and
FA, assessment of telomere lengths and chromosome fragility, respectively, are required.
(Figure 1). An integrated cyto-histologic/genetic score (hg-score) has been shown to be
useful to distinguish hMDS from AA [26,79] (Table 3). The correct diagnosis is especially
challenging in asymptomatic patients with moderate thrombocytopenia (PLT 50–100 G/L)
and otherwise unsuspicious peripheral blood values. The distinction from immunological,
infectious and toxic-reactive causes is critical, as the prognosis and evolution can differ
substantially depending on the underlying cause.
Table 3. Integrated cyto-histologic/genetic score (hg-score) for distinction of hypoplastic myelodys-
plastic syndrome (hMDS) and aplastic anemia (AA) [26].
Cytological/Histological Variables
Requisite criteria Scoring points
Bone marrow blasts AND/OR CD34 + cells ≥5% 2
Bone marrow blasts AND/OR CD34 + cells 2–4% 1
Fibrosis grade 2–3 1
Dysmegakaryopoiesis 1
Co-criteria
Ring sideroblasts ≥15% 2
Ring sideroblasts 5–14% * 1
Severe dysgranulopoiesis 1
Karyotype (co-criterion)
Presumptive cytogenetic abnormality * 2
Somatic mutation (co-criterion)
Specific high-risk mutation pattern ** 1
* According to World Health Organization (WHO) criteria [53] ** According to Malcovati et al. [79] Receiver
Operating Characteristic (ROC) analysis confirmed that a cutoff hg-score of 2 is associated with the highest
percentage of correctly classified (Area Under the Curve, (AUC) 0.89, p < 0.001).
Etiologies can also be multifactoral in elderly patients, i.e., transient aggravation of
thrombocytopenia can be observed during infections or drug-exposure in patients with
chronic, border-line thrombocytopenia. Delay in recovery after these intercurrences may
suggest deficiencies at the HSPC level.
4.2. Characterization of MDS
The challenge to distinguish reactive conditions from early stages of MDS has led an
international working group of MDS experts to define minimal diagnostic criteria required
for diagnosis of MDS (Table 4) [80]. MDS can develop either primarily or secondarily,
after previous radio- or chemotherapy, and are sub-classified according to the 2016 WHO
update (Table 5) [53]. Correct MDS sub-classification should be followed by appropriate
disease-based and patient-based risk stratification. The International Prognostic Scoring
System (IPSS), the revised IPSS (IPSS-R) as well as the WHO Prognostic Scoring System
(WPSS) can determine the risk for progression to AML and overall survival [45,46,81]. In
order to optimize efficacy against tolerability, patient-derived risk stratification is partic-
ularly important for elderly and frail MDS patients. Karnofsky and Eastern Cooperative
Oncology Group (ECOG) scores allow assessing the performance status but should be
complemented by assessment of comorbidity and frailty. The Charlson Comorbidity Index
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(CCI) was adapted by Sorror [82,83] and validated for MDS-patients that are sufficiently
fit for undergoing allo HSCT (hematopoietic stem cell transplantation comorbidity index:
HCT-CI) [84]. A simplified scoring system can be used for elderly MDS patients that
considers cardiac, pulmonary, renal and hepatic comorbidities as well as prior treatment
for solid tumors as most relevant factors (myelodysplastic syndromes comorbidity index:
MDS-CI) [85].
Table 4. Minimal diagnostic criteria for myelodysplastic syndromes (MDS) [80].
Criteria Major Diagnostic Tests
Prerequisite criteria (both must be fulfilled)
Constant cytopenia Blood counts (over 6 months)
Exclusion of all other diseases as primary cause of cytopenia⁄dysplasia BM smear and BM histology, cytogenetics, flow cytometry, molecularmarkers, other relevant investigations *
MDS-related criteria (one of these must be fulfilled)
Morphological dysplasia in one of the three major lineages BM and PB smear, in certain situations BM histology
Blast count ≥5% BM smear and histology
Ring sideroblasts ≥15% or ≥5% and SF3B1 mutation Iron staining
Typical karyotype anomaly Conventional karyotyping and/or FISH
Co-criteria
Monoclonality of myeloid cells Molecular markers and mutations
BM stem cell function Circulating CFC, reticulocytes
Abnormal immunophenotype of BM cells Multicolor flow cytometry, immunohistochemistry
Abnormal gene expression profile mRNA profiling assays
BM, bone marrow; PB, peripheral blood; FISH, fluorescence in situ hybridization; CFC, colony-forming progenitor cells. * Investigations
depend on the case history and overall situation in each case, and should always include a complete chemistry profile with inflammation
parameters, immunoglobulins, a serum erythropoietin level, and a serum tryptase level.
Table 5. WHO 2016 classification for Myelodysplastic Syndromes (MDS) [53].
Subtype 1 No. of DysplasticLineages
No. of Cytopenic
Lineages 2
% RS of all Erythroid
Cells in BM




wtSF3B1 mSF3B1 BM PB AR
MDS-SLD 1 1 or 2 <15 <5 <5 <1 -
MDS-MLD 2 or 3 1–3 <15 <5 <5 <1 -
MDS RS-SLD 1 1 or 2 ≥15 ≥5 <5 <1 -
MDS RS-MLD 2 or 3 1–3 ≥15 ≥5 <5 <1 -





MDS EB-1 0–3 1–3 n.a. n.a. 5–9 2–4 -
MDS EB-2 0–3 1–3 n.a. n.a. 10–19 5–19 +
MDS-U <15 <5 <5 <1 -
(a) 1% blasts in PB 1–3 1–3 n.a. n.a. <5 1 3 -
(b) SLD with
pancytopenia 1 3 n.a. n.a. <5 <1 -
(c) defining
cytogenetic aberration 0 1–3 <15




RCC 1–3 1–3 <15 ≤5 <5 <1 -
SLD: single-lineage dysplasia; MLD: multilineage dysplasia; RS: ring sideroblasts; EB: excess of blasts; RCC: refractory cytopenia of the
childhood; wt/mSF3B1: wild type or mutated SF3B1; PB: peripheral blood; BM: bone marrow; AR: Auer rods. 1 Without previous cytotoxic
treatment or germline predisposition for myeloid neoplasms. 2 Cytopenias: hemoglobin <100 g/L, thrombocytes <100 G/L, neutrophils
<1.8 G/L, monocytes <1 G/L. 3 1% blasts in PB must be confirmed with a 2nd analysis. 4 ≥15% RS corresponds to MDS-RS-SLD. CAVE:
If ≥50% are erythroid precursors and ≥20% blast cells of non-erythroid-lineage but <20% of all cells, this corresponds now to MDS
(MDS-SLD/MLD or EB) and not any more to AML M6 erythroid/myeloid.
4.3. Relevance of Thrombocytopenia in the Context of MDS Patients
Thrombocytopenia in MDS patients is mainly caused by insufficient or ineffective
thrombopoiesis, but some patients may have additional immunological mechanisms tar-
geting the mature platelets as well as the megakaryocytic progenitor cells in the bone
marrow [86]. In these circumstances, the morphological differential diagnosis between
MDS and immune thrombocytopenia (ITP) and the amegakaryocytic form of AA requires
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identification of characteristic genetic lesions. In retrospective studies, 12% of MDS patients
had isolated thrombocytopenia as first presentation [87] and 20% of patients, who were
initially classified as ITP, were reclassified with an unusual presentation of MDS [88]. In
a review of MDS patients referred to the MD Anderson Cancer Center, 67% of patients
were thrombocytopenic (PLT < 100 G/L), of which 26% had moderate (PLT 20–50 G/L)
and 17% severe (PLT < 20 G/L) thrombocytopenia [89]. Thrombocytopenia and severe
thrombocytopenia were more prominent in higher risk (77% and 20%) compared to lower
risk disease (51% and 12%) [89]. The impact of thrombocytopenia on morbidity and mor-
tality is relevant, as half of all MDS patients experience bleeding and a quarter experience
even serious bleedings during the course of disease [89,90]. Bleeding episodes can be
triggered by treatments with antiplatelet agents or anticoagulants for cardiovascular or
thromboembolic comorbidities. Bleeding can be related to quantitative thrombocytopenia
(PLT < 10–20 G/L) but also qualitative platelet defects (dysfunctional platelets) [91], caused
by somatic or germ-line mutations (i.e., ETV6, RUNX1, ANKR1) [92]. Isolated chronic
thrombocytopenia is rare in MDS patients as other lineages are frequently affected either
by mild cytopenia or dysplasia [93]. Based on the increased awareness of MDS, earlier
hematological assessment of mild cytopenias, and increased use of NGS panels, we and
others are currently observing an increasing number of patients with isolated thrombo-
cytopenia as initial manifestation of MDS. Other than that, primary myelofibrosis (PMF)
may also present with isolated thrombocytopenia. In such cases, splenomegaly may be
detected, accompanied by circulating dakryocytes, myeloid, or erythroid precursors and
thrombocyte anisocytosis [53].
4.4. Characterization of BMF
The rarity of AA, the difficulties in establishing the correct diagnosis due to the lack
of specific markers, and the overlaps with other disorders can delay its diagnosis. When
AA occurs in children, congenital forms should be considered. iBMF should be considered
in patients with a family history of cytopenias, tendency to cancer, or certain unexplained
liver or lung conditions independent of their age. In older adults, the discrimination from
hMDS is mandatory and particularly difficult (Tables 2 and 3).
Identifying the correct underlying disease has implications on the type of treatment.
For example, in patients with AA resulting from a nuclear accident as in Chernobyl, allo
HSCT is the only option [94], as damage of the hematopoietic cells will not respond to
immunosuppressive treatment. Following confirmation of AA and identification of the
underlying pathomechanism, its severity must be defined as basis for further therapeutic
decisions [95,96].
4.5. Isolated Thrombocytopenia as First Presentation of a BMF
Isolated thrombocytopenia will be interpreted and treated as ITP in some patients
and only in the course of the disease, a BMF will be finally diagnosed [97]. Nowadays, in
accordance with international guidelines, patients with suspected ITP do not necessarily
undergo bone marrow investigation [1], and marrow investigations will be done only after
failure of standard therapy. Some reports suggested that acquired amegakaryocytic throm-
bocytopenia may precede AA [98–100]. In cases of isolated thrombocytopenia, a detailed
personal and family medical history is mandatory, evaluating history of cytopenias, hema-
tological diseases, or a tendency to certain tumors. In a patient with thrombocytopenia,
the finding of dysmorphic nails, a history of gray hair early in life, café au lait spots, or
any type of physical dysmorphia may suggest an underlying iBMF. Likewise, a history of
fibrotic lung disease, liver, or skeletal changes are reasons to consider a consultation in a
specialized center [41].
4.6. Aplastic Anemia and PNH
PNH is a rare bone marrow failure disorder that manifests with hemolytic anemia,
thrombosis, and peripheral blood cytopenias. The absence of two glycosylphosphatidyli-
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nositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement
activation that accounts for hemolysis and other PNH manifestations [61]. PNH and AA
are related entities [101]. Patients with the typical hemolytic form of PNH can develop AA
and around 50% of patients with the acquired form of AA typically have PNH clones [102].
PNH clones accompanying AA are smaller than they are in the PNH hemolytic form. Flow
cytometry is the gold standard method for detection and diagnosis of PNH [103]. In AA,
PNH clones should be quantified at presentation and at follow-up by serial monitoring
every 6 to 12 months, even when the initial result was negative.
4.7. Inherited Bone Marrow Failures (iBMF)
In patients with BMF, a positive family history that includes other affected members
with cytopenia or malignancy suggests an iBMF. The presence of unusual clinical features
(skin, liver, lung, skeletal disease) should alert to the possibility of a congenital form of
BMF. A normal clinical examination does not definitively rule out asymptomatic forms
of telomeropathies or non-classical presentations of FA. If FA is suspected, investigations
that may demonstrate higher sensitivity to chromosomal breakage with mitomycin C or
diepoxybutane are necessary [104]. These investigations should be carried out in patients
with suspicion of an underlying iBMF. If the mitomycin C or diepoxybutane test is positive,
all family candidates to be donors for allo HSCT should also be investigated to rule
out asymptomatic forms of FA. In patients with FA, the correct diagnosis is of urgent
importance, as less toxic conditioning regimens are mandatory in the case of allo HSCT
due to defective DNA repair mechanisms.
Measurement of the telomere length of peripheral blood leukocytes can be performed
as a screening test in case of suspected telomeropathy. A variable percentage of patients
without telomeropathies will also show telomere attrition [23,24]. Mutations in the TERC
and TERT genes for example can cause telomeropathies in both children and adults [25].
When telomeropathies occur in adult patients they are more subtle in their clinical presen-
tation, which renders their detection difficult.
4.8. Future Challenges: Unexplained Thrombocytopenia with Clonal Hematopoiesis
After thorough diagnostic assessment, patients with unexplained thrombocytopenia
may show insufficient dysplastic morphological changes and lack MDS-defining cyto-
genetic alterations or sufficient criteria for BMF. These disease forms can be assigned to
Idiopathic Cytopenia of Unknown Significance (ICUS), if other clinical conditions are
insufficient to explain the cytopenia [80]. In the case that the severity of thrombocytopenia
imposes the need of therapeutic intervention, a steroid trial may be justified, whereas in
mild to moderate cases observation for 3–6 months is sufficient [105]. As shown in recent
years by numerous large studies, SM-LAGs can be identified by NGS in the peripheral
blood in an age-dependent, increasing frequency in the elderly population, in up to 20–40%
of individuals aged more than 80 years. These mutations are per se not indicative for a
hematological neoplasia [106–110], and the affected individuals have generally normal
peripheral blood values or only mild cytopenia that do not otherwise fulfill the diagnostic
criteria for a hematological malignancy [111]. In case that the variant allele frequency (VAF)
of the respective mutations is 2% or more, the condition is termed clonal hematopoiesis
with indeterminate potential (CHIP) in otherwise healthy individuals with normal blood
values, or clonal cytopenia with unknown significance (CCUS) in individuals with cytope-
nia, respectively [79,109]. CHIP and CCUS can be considered facultative precanceroses as
they are at an increased risk for transformation to overt hematological neoplasms in a rate
of 0.5–1% per year [111]. If SM-LAGs present with a VAF level ≥10% or with evidence
of two or more somatic associated mutations, a myeloid neoplasm can be diagnosed in
patients with unexplained cytopenia with a positive predictive value of >85% [79]. How-
ever, with the exception of mutations in spliceosome genes, single mutations in DNMT3A,
ASXL1 and TET2 (DAT mutations) with a VAF <10% are not sufficiently predictive for the
diagnosis of a myeloid malignancy, especially in elderly individuals [109]. On the contrary,
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a negative analysis with a panel of ≥40 genes can exclude a myeloid malignancy with a
negative predictive value of >80% [79]. In summary, the advent of NGS has substantially
increased the diagnostic sensitivity for detecting clonality and poses some novel challenges
in the correct interpretation of these results. Some of those patients will fulfill the criteria
for overt myeloid neoplasm as specified above, which will inevitably contribute to steadily
increasing incident cases of MDS and associated disorders.
5. Conclusions
• Unexplained chronic thrombocytopenia has to be considered as an early and unusual
presentation in MDS or BMF.
• Patient’s history remains crucial to identify suspicious cases and for the correct inter-
pretation of primary laboratory values.
• Various diagnostic modalities are required to confirm or exclude MDS or BMF and an
interdisciplinary workup is frequently required, especially in difficult cases.
• Meticulous assessment of the PB smear, BM cyto- and histomorphology, as well as cy-
togenetics are the mainstay of diagnostic evaluation, and is nowadays complemented
by NGS and other specialized analyses (telomere length, DNA breakage).
• Repeated bone marrow investigation may be necessary, especially in cases with
hypocellular BM for the distinction of sampling errors, reactive-toxic conditions,
BMF, and hypoplastic MDS.
• In some occasions, conclusive diagnosis is only possible after follow-up. How-
ever, NGS has substantially contributed in identifying early conditions of clonal
hematopoiesis, but additional challenges arise for classification and prognostication.
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